Bank of New York Mellon’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Bank of New York Mellon’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-23,601	Closed	-$215K	–	4479
2023 Q1	$215K	Sell	23,601 -224	-0.9%	-$3.17K	﹤0.01%	3889
2022 Q4	$280K	Sell	23,825 -453	-2%	-$7.99K	﹤0.01%	3826
2022 Q3	$514K	Buy	24,278 +2,109	+10%	+$56.9K	﹤0.01%	3551
2022 Q2	$538K	Buy	22,169 +173	+0.8%	+$5.89K	﹤0.01%	3544
2022 Q1	$1.09M	Buy	21,996 +204	+0.9%	+$10.1K	﹤0.01%	3251
2021 Q4	$1.53M	Sell	21,792 -58	-0.3%	-$4.89K	﹤0.01%	3148
2021 Q3	$2.04M	Buy	21,850 +1,793	+9%	+$170K	﹤0.01%	2962
2021 Q2	$2.02M	Sell	20,057 -3,705	-16%	-$361K	﹤0.01%	2976
2021 Q1	$2.22M	Sell	23,762 -822	-3%	-$83.3K	﹤0.01%	2872
2020 Q4	$2.03M	Buy	24,584 +4,973	+25%	+$424K	﹤0.01%	2837
2020 Q3	$1.68M	Sell	19,611 -1,663	-8%	-$194K	﹤0.01%	2762
2020 Q2	$1.98M	Buy	21,274 +5,439	+34%	+$300K	﹤0.01%	2686
2020 Q1	$451K	Buy	15,835 +10,432	+193%	+$406K	﹤0.01%	3429
2019 Q4	$224K	Hold	5,403	–	–	﹤0.01%	3886
2019 Q3	$76K	Buy	5,403 +190	+4%	+$3.98K	﹤0.01%	4065
2019 Q2	$183K	Buy	5,213 +4,346	+501%	+$236K	﹤0.01%	3939
2019 Q1	$49K	Sell	867 -194	-18%	-$10.5K	﹤0.01%	4093
2018 Q4	$51K	Buy	+1,061	New	+$58.2K	﹤0.01%	4058
2018 Q2	–	Sell	-2,370	Closed	-$248K	–	4323
2018 Q1	$248K	Buy	2,370 +87	+4%	+$10.4K	﹤0.01%	3858
2017 Q4	$293K	Buy	2,283 +803	+54%	+$98.7K	﹤0.01%	3806
2017 Q3	$171K	Sell	1,480 -5	-0.3%	-$601	﹤0.01%	3905
2017 Q2	$193K	Buy	+1,485	New	+$200K	﹤0.01%	3911

Other funds holding VBIV

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon's VBIV Position: Q2 2023 in Review

Bank of New York Mellon sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 23,601 shares — an estimated $215K sold.

Bank of New York Mellon first reported a position in VBIV in Q2 2017 and held it in 22 quarters. The position peaked at $2.22M in Q1 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

Bank of New York Mellon reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
Bank of New York Mellon sold 23,601 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $215K.
Bank of New York Mellon first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2017 and held it in 22 quarters.
Bank of New York Mellon's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $2.22M in Q1 2021.
46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.